Eli Lilly
Trade Eli Lilly 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About LLY
Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies.
LLY Key Statistics
LLY News
Novo Nordisk A/S NVO presented data from the STEER real-world study of evidence gathered from actual patient experiences at the European Society of Cardiology (...
Healthcare Eli Lilly posts late-stage trial win for Ozempic in children and adolescents with diabetes Sep. 18, 2025 7:17 AM ET Eli Lilly and Company (LLY) Stock...
Shares of Novo Nordisk (NVO) surged in pre-market hours after the healthcare company revealed its anti-obesity pill achieved nearly the same weight loss as its...
Analyst ratings
73%
of 30 ratingsMore LLY News
Eli Lilly (LLY) announced detailed results from SURPASS-PEDS, the first Phase 3 trial to evaluate the safety and efficacy of Mounjaro, a GIP/GLP-1 dual receptor...
If you own Eli Lilly stock or are thinking about jumping in, you are far from alone. With blockbuster drugs and market-shaking news around every corner, Eli Lil...
U.S. pharmaceutical giant Eli Lilly (LLY) says that it plans to submit its experimental weight-loss pill called Orforglipron for regulatory approval in several...
Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to...
The Department of Veterans Affairs posted a contract for Eli Lilly (LLY) worth up to $8B. Elevate Your Investing Strategy: Take advantage of TipRanks Premium...
Key Points Eli Lilly said its experimental pill outperformed Novo Nordisk's own oral drug in the first head-to-head study comparing the two medicines in patient...
Eli Lilly and Co LLY on Tuesday shared detailed results from the Phase 3 ATTAIN-1 trial, evaluating the safety and efficacy of oral orforglipron in adults with...
